OPUS GENETICS INC (IRD) Stock Fundamental Analysis
USA - NASDAQ:IRD - US67577R1023 - Common Stock
1.8 USD
-0.08 (-4.26%)
We assign a fundamental rating of 2 out of 10 to IRD. IRD was compared to 533 industry peers in the Biotechnology industry. Both the profitability and financial health of IRD have multiple concerns. While showing a medium growth rate, IRD is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year IRD has reported negative net income.
In the past year IRD has reported a negative cash flow from operations.
IRD had negative earnings in 4 of the past 5 years.
In the past 5 years IRD reported 4 times negative operating cash flow.
1.2 Ratios
IRD has a Return On Assets of -150.72%. This is amonst the worse of the industry: IRD underperforms 85.18% of its industry peers.
IRD has a worse Return On Equity (-333.51%) than 73.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -150.72% | ||
| ROE | -333.51% | ||
| ROIC | N/A |
ROA(3y)-46.02%
ROA(5y)-98.94%
ROE(3y)-68.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for IRD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IRD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IRD has been increased compared to 1 year ago.
The number of shares outstanding for IRD has been increased compared to 5 years ago.
There is no outstanding debt for IRD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
IRD has an Altman-Z score of -4.22. This is a bad value and indicates that IRD is not financially healthy and even has some risk of bankruptcy.
IRD's Altman-Z score of -4.22 is in line compared to the rest of the industry. IRD outperforms 43.53% of its industry peers.
A Debt/Equity ratio of 0.06 indicates that IRD is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.06, IRD is not doing good in the industry: 60.98% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.22 |
ROIC/WACCN/A
WACC8.78%
2.3 Liquidity
IRD has a Current Ratio of 1.90. This is a normal value and indicates that IRD is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of IRD (1.90) is worse than 77.30% of its industry peers.
IRD has a Quick Ratio of 1.90. This is a normal value and indicates that IRD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.90, IRD is doing worse than 75.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.9 | ||
| Quick Ratio | 1.9 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 23.85% over the past year.
The Revenue for IRD has decreased by -42.30% in the past year. This is quite bad
IRD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 165.10% yearly.
EPS 1Y (TTM)23.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.79%
Revenue 1Y (TTM)-42.3%
Revenue growth 3Y165.1%
Revenue growth 5YN/A
Sales Q2Q%-20.38%
3.2 Future
IRD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.87% yearly.
Based on estimates for the next years, IRD will show a very strong growth in Revenue. The Revenue will grow by 36.22% on average per year.
EPS Next Y48.71%
EPS Next 2Y27.42%
EPS Next 3Y16.75%
EPS Next 5Y14.87%
Revenue Next Year53.87%
Revenue Next 2Y49.99%
Revenue Next 3Y28.16%
Revenue Next 5Y36.22%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for IRD. In the last year negative earnings were reported.
Also next year IRD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as IRD's earnings are expected to grow with 16.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.42%
EPS Next 3Y16.75%
5. Dividend
5.1 Amount
IRD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:IRD (11/17/2025, 12:31:03 PM)
1.8
-0.08 (-4.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners20.88%
Inst Owner ChangeN/A
Ins Owners7.02%
Ins Owner Change7.08%
Market Cap113.49M
Revenue(TTM)10.99M
Net Income(TTM)-58.27M
Analysts81.82
Price Target7.87 (337.22%)
Short Float %0.69%
Short Ratio0.89
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.5%
Min EPS beat(2)4.95%
Max EPS beat(2)42.04%
EPS beat(4)3
Avg EPS beat(4)10.31%
Min EPS beat(4)-20.9%
Max EPS beat(4)42.04%
EPS beat(8)4
Avg EPS beat(8)-21.76%
EPS beat(12)6
Avg EPS beat(12)-14.42%
EPS beat(16)9
Avg EPS beat(16)-8.54%
Revenue beat(2)1
Avg Revenue beat(2)5.08%
Min Revenue beat(2)-29.45%
Max Revenue beat(2)39.62%
Revenue beat(4)3
Avg Revenue beat(4)29.95%
Min Revenue beat(4)-29.45%
Max Revenue beat(4)67.33%
Revenue beat(8)4
Avg Revenue beat(8)28.32%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-15%
PT rev (3m)-12.82%
EPS NQ rev (1m)1.52%
EPS NQ rev (3m)38.1%
EPS NY rev (1m)2.01%
EPS NY rev (3m)34.03%
Revenue NQ rev (1m)-4.05%
Revenue NQ rev (3m)-25.64%
Revenue NY rev (1m)-4.6%
Revenue NY rev (3m)-17.43%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.36 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.5 | ||
| P/tB | 6.5 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.83
EYN/A
EPS(NY)-0.41
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.5
OCFYN/A
SpS0.24
BVpS0.28
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -150.72% | ||
| ROE | -333.51% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-46.02%
ROA(5y)-98.94%
ROE(3y)-68.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.9 | ||
| Quick Ratio | 1.9 | ||
| Altman-Z | -4.22 |
F-Score2
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.79%
EPS Next Y48.71%
EPS Next 2Y27.42%
EPS Next 3Y16.75%
EPS Next 5Y14.87%
Revenue 1Y (TTM)-42.3%
Revenue growth 3Y165.1%
Revenue growth 5YN/A
Sales Q2Q%-20.38%
Revenue Next Year53.87%
Revenue Next 2Y49.99%
Revenue Next 3Y28.16%
Revenue Next 5Y36.22%
EBIT growth 1Y-152.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year128.22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-247.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-247.16%
OCF growth 3YN/A
OCF growth 5YN/A
OPUS GENETICS INC / IRD FAQ
Can you provide the ChartMill fundamental rating for OPUS GENETICS INC?
ChartMill assigns a fundamental rating of 2 / 10 to IRD.
What is the valuation status of OPUS GENETICS INC (IRD) stock?
ChartMill assigns a valuation rating of 0 / 10 to OPUS GENETICS INC (IRD). This can be considered as Overvalued.
Can you provide the profitability details for OPUS GENETICS INC?
OPUS GENETICS INC (IRD) has a profitability rating of 0 / 10.
Can you provide the financial health for IRD stock?
The financial health rating of OPUS GENETICS INC (IRD) is 2 / 10.